Ειδήσεις: BICARA THERAPEUTICS | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

01/04 11:43 defenseworld.net

The Goldman Sachs Group Issues Positive Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price

Bicara Therapeutics Goldman Sachs price target stock rating market optimism Wedbush

01/04 10:16 defenseworld.net

Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $42.00 at HC Wainwright

Bicara Therapeutics price target HC Wainwright analyst ratings Citigroup Weiss Ratings

30/03 19:41 yahoo.com

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?

Bicara Therapeutics CEO share sale stock analysis insider trading investment outlook biotech

26/03 10:30 defenseworld.net

Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated by Analysts at Bank of America

Bicara Therapeutics Bank of America buy rating price target NASDAQ analysts

25/03 18:36 investing.com

Bicara Therapeutics stock gains on BofA initiation

Bicara Therapeutics Bank of America stock gains analyst upgrade clinical trials market potential

24/03 18:09 defenseworld.net

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $30.25 Consensus PT from Brokerages

Bicara Therapeutics BCAX analyst ratings price target moderate buy sell

24/03 18:09 defenseworld.net

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $30.25 Consensus PT from Brokerages

Bicara Therapeutics BCAX analyst ratings price target moderate buy sell

Loading...